Activists press Alexion for stepped-up guidance, boardroom edits: report

8th December 2017 Uncategorised 0

Thanks to recent “turmoil” at the company, Leerink Partners analyst Geoffrey Porges has called Alexion “one of the rare, once or twice per decade, activist investment situations in the biopharmaceutical industry.” And one prominent activist reportedly wants to take advantage of the opportunity.

More: Activists press Alexion for stepped-up guidance, boardroom edits: report
Source: fierce